Immune Correlates Analysis of the ENSEMBLE Single Ad26.COV2.S Dose Vaccine Efficacy Clinical Trial

Scientists analyzed binding and neutralizing antibody measurements fiour weeks post vaccination as correlates of risk of moderate to severe-critical COVID-19 through 83 d post vaccination in the Phase III, double-blind placebo-controlled phase of ENSEMBLE, an international randomized efficacy trial of a single dose of Ad26.COV2.S.